Hyperinflation refers to the lung’s increase in size due to the trapped air that has caused them to expand. The BREATHE-3 trial uses self-expanding nitinol airway scaffolds that are placed ...

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...

NORTH PHILADELPHIA (WPVI) -- There's a potential new treatment for severe emphysema, and Philadelphia is a key test site for this small device with big potential to improve lives. In COPD (Chronic ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive ...

Visually assessed pulmonary emphysema independently predicted modestly elevated all-cause mortality risk over 25 years of follow-up in patients with a history of smoking. After controlling for other ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive ...

After emerging from stealth earlier this year, Apreo Health has raised $130 million to breathe new life into the development of lung implants for emphysema. The financing comes through a series B ...

More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

Dupilumab is now approved for bullous pemphigoid, showing efficacy in achieving sustained disease remission and reducing severity. The LIBERTY-BP ADEPT study demonstrated significant improvements in ...